Starting from the Philadelphia positive leukemia model, in which mechanisms of resistance to TKIs have been widely investigated and described [32], due to their clinical implications in patients’ management, the same topic has also been addressed in AML, in order to investigate the variable sensitivity of FLT3 inhibitors between different activating point mutations in the kinase domain of FLT3. Here, FLT3 is linked to leukemia.